05.26.26 -- April 2026 — CDMO Opportunities And Threats Report

Watch as our CGT experts explore the evolving landscape of viral vector manufacturing, overcoming production bottlenecks, and the strategies necessary to bring life-changing therapies to more patients.

This disposable pen for Semaglutide is a generic drug-device combination, designed for usability and regulatory compliance, showing comparable performance to the reference device.

Discover how a CDMO with extensive experience in protein variant characterization, CQA analytics, and patient-centric product development can ensure the safety and efficacy of your biotherapeutic.

Take a look at how gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

Developability assessments flag early risks in stability, manufacturability, and biophysics, helping teams focus on candidates most likely to succeed clinically and commercially.

Viral clearance studies face regulatory uncertainty, process limits, timeline pressure, and design challenges, demanding phase‑appropriate, flexible strategies for reliable outcomes.

A biotech company accelerated NDA approval for a novel anti‑infective by executing a highly disciplined, first‑time‑right technology transfer and registration batch manufacturing strategy.

See state‑of‑the‑art analytical methods for AAV characterization, key quality attributes to monitor, and approaches for measuring infectivity and full‑to‑empty capsid ratios.

Gain insight into how automation and digitalization are transforming cell and gene therapy with scalable, decentralized manufacturing and smarter market navigation.

JHS partnered with a global pharma company to optimize biologic production, increasing output by 50% and reducing batch release times by up to 30%.

Find out how one family's race against time led to the creation of a groundbreaking gene therapy for their daughter, just 14 months after her ultra-rare disease diagnosis.

Stability testing is essential to ensuring your drug’s stability, potency, efficacy, and safety under different controlled conditions throughout development, manufacturing, and life cycle management.